Priyanka Chopra Jonas and Crocs to Donate 50,000 Pairs of Classic Clogs to UNICEF
12.12.2019 16:00:00 EET | Business Wire | Press release
Crocs, Inc. (NASDAQ: CROX), in partnership with UNICEF Goodwill Ambassador Priyanka Chopra Jonas, today announced that 50,000 pairs of Crocs Classic clogs will be donated over the next year to underserved school children in Belize through UNICEF. This charitable contribution supports the actor’s joint mission to help children around the world and provide them with more opportunities to achieve an education.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005213/en/
In partnership with UNICEF Goodwill Ambassador and Crocs Global Brand Ambassador Priyanka Chopra Jonas, Crocs recently donated 25,000 pairs of Classic Clogs to underserved school children in Belize through UNICEF. This is the first of two donations to be made to this region through this partnership. A total of 50,000 pairs will ultimately be donated over the next year. (Photo: Business Wire)
Recently, Crocs announced award-winning actor, activist, and entrepreneur Priyanka Chopra Jonas would serve as a global brand ambassador for its 2020 “Come As You Are” marketing campaign. A special element of the partnership is this collaboration to jointly support UNICEF.
“At Crocs, we believe being comfortable in your own shoes is a first step to accessing quality education,” said Heidi Cooley, Vice President of Global Marketing, Crocs. “With this donation, we hope to deliver shoes to more than half of the student population attending primary and secondary school classes in Belize, while reducing the financial burden for their families.”
“As a global ambassador for UNICEF, I’m dedicated to connecting organizations that together can have a large and positive impact on children around the world,” said Priyanka Chopra Jonas. “Working with Crocs to distribute more than 50,000 pairs of their Classic Clogs will have a tremendous impact on school-age children in Belize, reducing barriers to education, and easing social and peer-related stressors that come with not having basic everyday resources that many take for granted.”
Barriers to education in Belize include poverty, disability, late entry, and inadequate preparation for primary school, among other factors. In November, members of UNICEF USA and Crocs visited Belize, where they distributed an initial 25,000 pairs of Crocs – the first of two parts of this donation – to students. A video documenting that journey and showing first-hand the positive impact of the contribution can be found linked here.
“UNICEF USA is grateful for Crocs’ generous shoe donation to help remove one of the barriers that can hinder school attendance in Belize, especially during early childhood education,” said Gabriella Morris, Senior Vice President of Strategic Partnerships, UNICEF USA. “Education is essential for children to live to their fullest potential, and together, we can help give each child the opportunity for quality education.”
About Crocs, Inc.
Crocs, Inc. (NASDAQ: CROX) is a world leader in innovative casual footwear for women, men, and children, combining comfort and style with a value that consumers know and love. Crocs’ proprietary Croslite™ material, a molded footwear technology, is included in the vast majority of Crocs’ collection and delivers extraordinary comfort with each step.
In 2019, Crocs declares that expressing yourself and being comfortable are not mutually exclusive. To learn more about Crocs or our global Come As You Are™ campaign, please visit www.crocs.com or follow @Crocs on Facebook, Instagram, and Twitter.
About UNICEF
The United Nations Children's Fund (UNICEF) works in more than 190 countries and territories to put children first. UNICEF has helped save more children’s lives than any other humanitarian organization, by providing health care and immunizations, clean water and sanitation, nutrition, education, emergency relief, and more. UNICEF USA supports UNICEF's work through fundraising, advocacy, and education in the United States. Together, we are working toward the day when no children die from preventable causes and every child has a safe and healthy childhood. For more information, visit www.unicefusa.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005213/en/
Contact information
Media Contacts:
Crocs
Melissa Layton
mlayton@crocs.com
UNICEF
Ann Reinking Whitener
areinking@unicefusa.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom